|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
LIN CHIH HUI | LIN CHIH HUI | To be filled | (02)8797-7100 | 11TH FL., NO.396, SEC. 1, NEIHU ROAD,TAIPEI, TAIWAN, R.O.C. | 2003/05/12 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | SYNMOSA BIOPHARMA is professional selling expertise in HRT, CV, Resp and NSAIDs. The current sales are constituted from six therapeutic areas: cardiovascular, respiratory, Hormone replacement therapy, CNS, metabolic, and NSAIDs.we keep putting in resources to develop the sales in these areas.We're prospecting to promote our global presence by cooperation with global companies. And would like to expand it's business by exporting or franchise it branded products to local buyers. |
Market Information ( 2024/04/24 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
907.982 | 38.30 | 38.10 | 38.20 | 0.05 | 698 | .00 | 9,113 | 4 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/24) |
TPEx measures adopted (2024/04/24) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | Y | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |